The focus of this proposal is the link between P53-mediated apoptosis and DNA damage repair, and the possibility of exploiting these pathways to overcome therapy resistance in glioblastoma. This tumor is characterized by an unusually malignant nature, by frequent P53 mutation (50% overall) and by high resistance to all forms of presently available therapy. We have found that glioblastoma cells expressing endogenous mutant P53 become much more sensitive to cisplatin and radiation-induced apoptosis following gene transfer of wild-type P53, even under conditions where overall growth of the cells is not significantly changed. In light of the potential clinical interest of this observation for glioblastoma, the project will address: (1) the generality of the sensitization effect in vitro with respect to different P53 mutations, including those which act as dominant-negatives, and with respect to different drugs, (2) The role of DNA-mediated suppression. In particular, we will explore a novel approach to therapy sensitization using P53 along with inhibitors of the AP-1 transcription factor which regulates expression of several DNA repair enzymes. The combined effects will be examined of P53 with each of two AP-1 inhibitors, a dominant-negative inhibitor of c-jun (mutant jun) that inhibits the phosphorylation-rated functions a AP-1 associated with cellular transformation, and the synthetic retinoid, SR11220, capable of down-regulating AP-1 activity, (3) The specific components of DNA repair that affect P53-mediated suppression, (4) The in vivo application of P53 combination approaches using a subcutaneous nude mouse model and a fisher rat intracranial model of glioblastoma. These studies are designed to provide a rigorous pre-clinical evaluation of P53-mediated growth suppression and therapy sensitization, and to fully explore the combine potential of P53 and ap-1 inhibitors, as potential second generation anti-cancer agents with specificity for tumor cells. The studies will also provide insight into the fundamental nature of drug and radiation resistance in glioblastoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA069546-02
Application #
2733206
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Wolpert, Mary K
Project Start
1997-07-07
Project End
2002-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Sidney Kimmel Cancer Center
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121
Huang, Yinghui; Lee, Casey; Borgstrom, Per et al. (2007) Macrophage-mediated bystander effect triggered by tumor cell apoptosis. Mol Ther 15:524-33
Huang, Yinghui; Tyler, Traci; Saadatmandi, Neshat et al. (2003) Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability. Cancer Res 63:3646-53
Saadatmandi, Neshat; Tyler, Traci; Huang, Yinghui et al. (2002) Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status. Cancer Gene Ther 9:830-9
Gjerset, R; Haghighi, A; Lebedeva, S et al. (2001) Gene therapy approaches to sensitization of human prostate carcinoma to cisplatin by adenoviral expression of p53 and by antisense jun kinase oligonucleotide methods. Methods Mol Biol 175:495-520
Lebedeva, S; Bagdasarova, S; Tyler, T et al. (2001) Tumor suppression and therapy sensitization of localized and metastatic breast cancer by adenovirus p53. Hum Gene Ther 12:763-72
Gjerset, R A; Mercola, D (2000) Sensitization of tumors to chemotherapy through gene therapy. Adv Exp Med Biol 465:273-91
Gjerset, R A; Lebedeva, S; Haghighi, A et al. (1999) Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification. Cell Growth Differ 10:545-54
Haghighi, A; Lebedeva, S; Gjerset, R A (1999) Preferential platination of an activated cellular promoter by cis-diamminedichloroplatinum. Biochemistry 38:12432-8
Dorigo, O; Turla, S T; Lebedeva, S et al. (1998) Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J Neurosurg 88:535-40